血栓通联合阿托伐他汀治疗急性冠脉综合征的临床研究

The Clinical Research on Xueshuantong Combined with Atorvastatin in Treatment of Acute Coronary Syndrome

目的:探讨血栓通联合阿托伐他汀治疗急性冠脉综合征的临床效果。方法:选取本院2011年4月-2013年4月诊治的急性冠脉综合征患者96例,根据治疗方案分为两组,48例患者采用阿托伐他汀治疗为对照组,48例患者采用血栓通联合阿托伐他汀治疗为观察组,疗程4周,比较两组患者的临床指标、治疗效果、心脑血管事件情况。结果:观察组患者总胆固醇、三酰甘油、低密度脂蛋白胆固醇、C反应蛋白、B型脑钠肽均明显小于对照组,两组比较差异均有统计学意义(P<0.05);观察组患者高密度脂蛋白胆固醇、总有效率均明显高于对照组,两组比较差异均有统计学意义(P<0.05);观察组患者心脑血管事件发生率明显低于对照组,两组比较差异均有统计学意义(P<0.05)。结论:血栓通联合阿托伐他汀可明显改善急性冠脉综合征患者的临床指标,提高治愈率,心脑血管事件少且安全性高,值得临床推广使用。

Objective： To investigate the clinical effect of xueshuantong combined with atorvastatin in treatment of acute coronary syndrome. Method： Ninety-six patients with acute coronary syndrome were selected in hospital from April 2011 to April 2013. According to treatment, patients were divided into two groups. Forty-eight patients treated by atorvastatin as control group. Forty-eight patients treated by xueshuantong combined with atorvastatin as observation group. Course of treatment was 4 weeks. Clinical parameters, treatment effect, cardiovascular cerebrovascular events were compared between two groups. Result： Total cholesterol, trigIycerides, LDL cholesterol, C-reactive protein, B-type natriuretic peptide of observation group were significantly less than those of the control group, and the differences between the two groups were all statistically significant （ P〈0.05 ） . HDL cholesterol, total effective rate in observation group were significantly higher than those of the control group, and the difference between the two groups were all statistically significant （ P〈0.05 ） . Incidence of cardiovascular cerebrovascular events of observation group was significantly lower than that of control group, and the difference between the two groups was all statistically significant （ P〈O.05 ） . Conclusion： Xueshuantong combined with atorvastatin can significantly improve clinical parameters of patients with acute coronary syndrome, which can also improve cure rate. Xueshuantong combined with atorvastatin have fewer cardiovascular cerebrovascular events and high safety, which is worthy of clinical use.